Antigen-Peptide-Transporter 2 Deficiency Overview
Learn About Antigen-Peptide-Transporter 2 Deficiency
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Jason Fisher is a Pediatric Surgeon and a General Surgeon in New York, New York. Dr. Fisher is rated as an Advanced provider by MediFind in the treatment of Antigen-Peptide-Transporter 2 Deficiency. His top areas of expertise are Bare Lymphocyte Syndrome, Antigen-Peptide-Transporter 2 Deficiency, Imperforate Anus, Appendectomy, and Oophorectomy.
Sylvia Santosa practices in Montreal, Canada. Ms. Santosa is rated as a Distinguished expert by MediFind in the treatment of Antigen-Peptide-Transporter 2 Deficiency. Her top areas of expertise are Antigen-Peptide-Transporter 2 Deficiency, Obesity, Isolated Hypogonadotropic Hypogonadism, Hypogonadotropic Hypogonadism, and Orchiectomy.
Gokhan Cesur practices in Aydin, Turkey. Cesur is rated as a Distinguished expert by MediFind in the treatment of Antigen-Peptide-Transporter 2 Deficiency. Their top areas of expertise are Antigen-Peptide-Transporter 2 Deficiency, Methimazole Antenatal Exposure, Hypothyroidism, and Congenital Hypothyroidism.
Summary: This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blin...
Summary: Owing to the rarity, severity, speed of progression and fatal prognosis of infantile and juvenile GM1, there is a limited understanding of overall disease progression and meaningful outcome measures. This study aims to build a natural history data set through collection of a number of clinical, imaging, and laboratory assessments that may be specific predictors of GM1 disease progression and clini...